Literature DB >> 15519905

The [3H]dofetilide binding assay is a predictive screening tool for hERG blockade and proarrhythmia: Comparison of intact cell and membrane preparations and effects of altering [K+]o.

Gilbert J Diaz1, Katina Daniell, Sandra T Leitza, Ruth L Martin, Zhi Su, Jeffrey S McDermott, Bryan F Cox, Gary A Gintant.   

Abstract

INTRODUCTION: The human ether-a-go-go-related gene (hERG) encodes a potassium channel responsible for the cardiac delayed rectifier current (IKr) involved in ventricular repolarization. Drugs that block hERG have been associated with QT interval prolongation and serious, sometimes fatal, cardiac arrhythmias (including torsade de pointes). While displacement of [3H]dofetilide, a potent methanesulfonanilide hERG blocker, from cells heterologously expressing hERG has been suggested as a screening assay, questions have been raised about its predictive value.
METHODS: To validate the utility of this assay as a screening tool, we performed a series of saturation and competition binding studies using [3H]dofetilide as ligand and either intact cells or membrane preparations from HEK 293 cells stably transfected with hERG K+ channels. The object of these experiments was to (1) compare binding Ki values for 22 hERG blockers using intact cells or membrane homogenates to determine whether maintaining cell integrity enhanced assay reliability; (2) evaluate the ability of different K+ concentrations (2, 5, 10, 20, and 60 mM) to modulate hERG binding; and (3) to establish the predictive value of the assay by comparing Ki values from binding studies at 5 and 60 mM [K+]o to functional IC50 values for hERG current block using 56 structurally diverse drugs.
RESULTS: We found (a) comparable Ki values in the intact cell and isolated membrane binding assays, although there were some differences in rank order; (b) increasing [K+]o lowered the Kd and increased the Bmax for [3H]dofetilide, particularly in the membrane assay; and (c) good correlation between binding Ki values and functional IC50 values for hERG current block. DISCUSSION: In conclusion, increasing K+ concentrations results in an increase in both [3H]dofetilide affinity for hERG and available binding sites, particularly when using membrane homogenates. There are no meaningful differences between Ki values when comparing intact cell versus membrane assay, neither are there meaningful trends with increasing [K+]o within assays. There is good correlation between binding Ki values and functional (whole-cell patch clamp) IC50 values at both 5 and 60 mM K+ concentrations (R2 values of .824 and .863, respectively). The simplicity, predictability, and adaptability to high-throughput platforms make the [3H]dofetilide membrane binding assay a useful tool for screening and ranking compounds for their potential to block the hERG K+ channel.

Entities:  

Mesh:

Substances:

Year:  2004        PMID: 15519905     DOI: 10.1016/j.vascn.2004.04.001

Source DB:  PubMed          Journal:  J Pharmacol Toxicol Methods        ISSN: 1056-8719            Impact factor:   1.950


  20 in total

Review 1.  High throughput screening technologies for ion channels.

Authors:  Hai-bo Yu; Min Li; Wei-ping Wang; Xiao-liang Wang
Journal:  Acta Pharmacol Sin       Date:  2015-12-14       Impact factor: 6.150

Review 2.  Preclinical characterization of A-582941: a novel alpha7 neuronal nicotinic receptor agonist with broad spectrum cognition-enhancing properties.

Authors:  Karin R Tietje; David J Anderson; R Scott Bitner; Eric A Blomme; Paul J Brackemeyer; Clark A Briggs; Kaitlin E Browman; Dagmar Bury; Peter Curzon; Karla U Drescher; Jennifer M Frost; Ryan M Fryer; Gerard B Fox; Jens Halvard Gronlien; Monika Håkerud; Earl J Gubbins; Sabine Halm; Richard Harris; Rosalind J Helfrich; Kathy L Kohlhaas; Devalina Law; John Malysz; Kennan C Marsh; Ruth L Martin; Michael D Meyer; Angela L Molesky; Arthur L Nikkel; Stephani Otte; Liping Pan; Pamela S Puttfarcken; Richard J Radek; Holly M Robb; Eva Spies; Kirsten Thorin-Hagene; Jeffrey F Waring; Hilde Ween; Hongyu Xu; Murali Gopalakrishnan; William H Bunnelle
Journal:  CNS Neurosci Ther       Date:  2008       Impact factor: 5.243

3.  Compilation and physicochemical classification analysis of a diverse hERG inhibition database.

Authors:  Remigijus Didziapetris; Kiril Lanevskij
Journal:  J Comput Aided Mol Des       Date:  2016-10-25       Impact factor: 3.686

4.  Kv 11.1 (hERG)-induced cardiotoxicity: a molecular insight from a binding kinetics study of prototypical Kv 11.1 (hERG) inhibitors.

Authors:  Z Yu; A P IJzerman; L H Heitman
Journal:  Br J Pharmacol       Date:  2014-12-15       Impact factor: 8.739

5.  Design, Synthesis, and Biological Evaluation of Novel Conformationally Constrained Inhibitors Targeting EGFR.

Authors:  Jianwei Wu; Wenteng Chen; Guangxin Xia; Jing Zhang; Jiaan Shao; Biqin Tan; Chunchun Zhang; Wanwan Yu; Qinjie Weng; Haiyan Liu; Miao Hu; Hailin Deng; Yu Hao; Jingkang Shen; Yongping Yu
Journal:  ACS Med Chem Lett       Date:  2013-08-06       Impact factor: 4.345

6.  Astemizole Derivatives as Fluorescent Probes for hERG Potassium Channel Imaging.

Authors:  Beilei Wang; Zhenzhen Liu; Zhao Ma; Minyong Li; Lupei Du
Journal:  ACS Med Chem Lett       Date:  2016-01-20       Impact factor: 4.345

Review 7.  The future of toxicity testing: a focus on in vitro methods using a quantitative high-throughput screening platform.

Authors:  Sunita J Shukla; Ruili Huang; Christopher P Austin; Menghang Xia
Journal:  Drug Discov Today       Date:  2010-08-11       Impact factor: 7.851

8.  Astemizole-based turn-on fluorescent probes for imaging hERG potassium channel.

Authors:  Xiaomeng Zhang; Tingting Liu; Beilei Wang; Yuqi Gao; Pan Liu; Minyong Li; Lupei Du
Journal:  Medchemcomm       Date:  2019-02-26       Impact factor: 3.597

9.  Molecular determinants of hERG channel block by terfenadine and cisapride.

Authors:  Kaichiro Kamiya; Ryoko Niwa; Mikio Morishima; Haruo Honjo; Michael C Sanguinetti
Journal:  J Pharmacol Sci       Date:  2008-11-06       Impact factor: 3.337

10.  Structure-based design of substituted piperidines as a new class of highly efficacious oral direct Renin inhibitors.

Authors:  Takeru Ehara; Osamu Irie; Takatoshi Kosaka; Takanori Kanazawa; Werner Breitenstein; Philipp Grosche; Nils Ostermann; Masaki Suzuki; Shimpei Kawakami; Kazuhide Konishi; Yuko Hitomi; Atsushi Toyao; Hiroki Gunji; Frederic Cumin; Nikolaus Schiering; Trixie Wagner; Dean F Rigel; Randy L Webb; Jürgen Maibaum; Fumiaki Yokokawa
Journal:  ACS Med Chem Lett       Date:  2014-04-21       Impact factor: 4.345

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.